AZD-929 1 (osetinib) is a highly selective EGFR mutation inhibitor. The IC50 of EGFR with exon 19 deletion, L858R/T790MEGFR and wild-type EGFR were 12.92nM, 1 1.44nM and 493.8, respectively. The molecular weight is 499.6 1 and the molecular formula is C28H33N7O2.
AZD-929 1 can be used to develop drugs for advanced non-small cell lung cancer and oral drugs for patients with advanced non-small cell lung cancer. At the same time, the treatment effect is very obvious for patients with advanced lung cancer who take domestic kemena, gefitinib (Iressa) and erlotinib hydrochloride (Trafigura).